Open access · CC-BY
via OpenAlex
The efficacy and tolerability of intermittent prandial acarbose to reduce glucose spikes in healthy individuals
Anar Isman, Andy Nyquist, Mauricio Moel, X. Zhang, Sajad Zalzala
Translational Medicine of Aging · 2023 · ▲ 6 citations
Abstract
Acarbose is an α-glucosidase inhibitor that slows the digestion of carbohydrates and can prevent sharp increases in blood sugar levels after meals (spikes). Excessive postprandial blood glucose spikes have been associated with chronic conditions, increase all-cause mortality, and may contribute to aging. Therefore, the prevention of glucose spikes may contribute to the preservation of human healthspan(definition). Indeed, acarbose has been associated with increased lifespan in animal models. However, its tolerability profile has limited acarbose use in healthy individuals. We hypothesized that using low-dose acarbose right before the occasional high-carbohydrate meal may prevent glucose spikes in healthy individuals. We performed a prospective clinical study to evaluate the tolerability and efficacy of acarbose in healthy individuals. Participants were randomized into two arms, each performing two control tests and two treatment tests. Continuous glucose monitor (CGM) measurements were collected for 2 h after high carbohydrate meals with or without pre-meal 50 mg acarbose intake. Tolerability was assessed using questionnaires. Twelve patients had evaluable results. Acarbose pretreatment resulted in reductions in CGM glucose measurements, with a significant decrease in glucose levels at the start, after 15 min, and at peak glucose levels. Few participants reported acarbose adverse events, and these included flatulence, bloating, nausea, abdominal pain, and stomach aches. No statistical difference in tolerability was detected between periods with and without acarbose. In conclusion, treatment with 50 mg of acarbose before meals was found to be well tolerated and efficacious in blunting the postprandial glucose spike by over 17% in healthy individuals.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1016/j.tma.2023.04.002
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Isman, A., Nyquist, A., Moel, M., Zhang, X., & Zalzala, S. (2023). The efficacy and tolerability of intermittent prandial acarbose to reduce glucose spikes in healthy individuals. <em>Translational Medicine of Aging</em>. https://doi.org/10.1016/j.tma.2023.04.002
Vancouver
Isman A, Nyquist A, Moel M, Zhang X, Zalzala S. The efficacy and tolerability of intermittent prandial acarbose to reduce glucose spikes in healthy individuals. Translational Medicine of Aging. 2023. doi:10.1016/j.tma.2023.04.002.
BibTeX
@article{anar2023Theeff,
title = {The efficacy and tolerability of intermittent prandial acarbose to reduce glucose spikes in healthy individuals},
author = {Anar Isman and Andy Nyquist and Mauricio Moel and X. Zhang and Sajad Zalzala},
journal = {Translational Medicine of Aging},
year = {2023},
doi = {10.1016/j.tma.2023.04.002},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Archives of Ophthalmology 1999
Open access · OA
Photodynamic Therapy With Verteporfin for Choroidal Neovascularization Caused by Age-related Macular Degeneration
The Journal of Clinical Endocrinology & Metabolism 2013
Citation only
Metabolic Signature Shift in Type 2 Diabetes Mellitus Revealed by Mass Spectrometry-based Metabolomics
Baskent University 2026
Open access · US-GOV
Comparison of Frailty, Physical Fitness Parameters, and Irisin Levels Between Patients With Multiple Sclerosis and Healthy Volunteers
Rishi Singh 2012
Open access · US-GOV
A Single Arm, Investigator Initiated Study of the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Injection in Subjects With Exudative Age-related Macular Degeneration Previously Treated With Ranibizumab or Bevacizumab (ASSESS Study)
GlaxoSmithKline 2010
Open access · US-GOV
MD7110852, A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops Versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration
BMC psychiatry 2026
Open access · OA